** Shares of biopharmaceutical company Gilead Sciences GILD.O fall 2.9% to $115.34 in premarket
** Reuters reports CVS Health CVS.N to not add Gilead's new HIV prevention drug Yeztugo to its commercial plans for now
** CVS cites clinical, financial, and regulatory reasons for decision, a spokesperson told Reuters
** Adds, won't cover Yeztugo under its Affordable Care Act formularies, which follow U.S. Department of Health and Human Services (HHS) recommendations
** Gilead still negotiating with CVS over Yeztugo; U.S. list price more than $28,000/year
** Co aims for 75% U.S. insurer coverage by year-end and 90% by June 2026
** A majority of brokerages rate the stock "buy" or higher; their median PT is $128
** Up to last close, stock had risen over 28.5% YTD